Bolt Biotherapeutics, Inc. — Director's Dealing 2021

Feb 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2021-02-04

Reporting Person: Schatzman Randall C (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-04	Stock Option (Right to Buy)	$20.00	A	340000	Acquired	2031-02-03	Common Stock (340000)	Direct

Footnotes

F1: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/48th of the Shares will vest upon the Reporting Person completing each month of continuous service following February 4, 2021.